Taiwan business watch 2023: Biomedical sector by revenue｜Institute for Biotechnology and Medicine Industry│IBMI

Industry Watch

Taiwan business watch 2023: Biomedical sector by revenue

2024-01-19

上一則

下一則

回列表頁

｜

The currency used in this article is the Taiwan Dollar, often referred to as NT$; the amount shown in the article is rounded.

The year 2023 posts $319bn in revenue, up 4.8%

Charts or tables shown below cover 224 companies listed on the Taipei Exchange (TPEx) and trading in OCT and emerging stock markets.
Total revenue of 2023 increased by $146bn to nearly $319bn, a 4.8% growth over the previous year.

Biomedical Industry Revenue 2018-2023

Year	2018	2019	2020	2021	2022	2023
Revenue(TWD, 100M)	2507	2475	2531	2913	3041	3187
YoY Growth	10.9%	-1.3%	2.3%	15.1%	4.4%	4.8%

Note: Dyaco International, Johnson Health Tech and Chi Hua Fitness have moved from the category “Healthcare” to “Sports and Recreation” since July 2023, hence the exclusion of their revenue.

One third of total revenues generated by bio-pharmaceutical sector

“Bio-Pharmaceuticals” ended the year at over $100 billion, an increase of $11.2bn compared to last year.
“Medical Device R&D, Manufacturing” amounted to $71.1bn, despite a $5.1bn drop.
“Pharmacy & Distributor” climbed to $70.6bn, making almost $4.1bn more than that of 2022.

Biomedical sectors by revenue 2022-2023 (listed and unlisted combined)

Pharmacy & distributor sector tops average revenue

“Pharmacy & Distributor” sector has 19 companies that made $3.71bn in average- the highest among others.
Seven companies under “APIs” reached $1.93bn.
14 companies under “Food Science & Health Supplements” ranked third with an average turnover of $18.2bn.

Cellular-related sector takes crown for year-on-year growth

"Cell Therapy" sector is still relatively new to the following chart, despite its impressive 38% growth rate.
"Aesthetic Medicine & Beauty Care" came second with 15.41%, followed by Bio-Pharmaceuticals with 13.87%.
Some sectors faced headwinds, namely "Genetic Testing & Wellness Check" at -7.67%, "Medical Device R&D, Manufacturing" at -6.75%, and "Agriculture & Agricultural Science" at -3.48%.

Overview of revenue 2023 with average and year-on-year growth

Business focus / product types	Q1-Q4, 2023			Q1-Q4, 2022	YoY Growth (%)	Top 3 by Revenue 2023
Business focus / product types	No. of Company	Total Revenue (TWD, 100M)	Average Revenue (TWD, 100M)	Total Revenue (TWD, 100M)	YoY Growth (%)	Top 3 by Revenue 2023
Bio-Pharmaceuticals	73	1004.55	13.76	882.17	13.87	Lotus Pharmaceutical Co., Ltd. $17.0bn Bora Pharmaceuticals Co., LTD. $14.2bn China Chemical & Pharmaceutical Co., Ltd. $8.6bn
Medical Device R&D, Manufacturing	66	711.25	10.78	762.74	-6.75	Pegavision Corporation $6.8bn TaiDoc Technology Corporation $4.8bn BenQ Medical Technology Corporation $4.5bn
Pharmacy & Distributor	19	706.01	37.16	665.3	6.12	Great Tree Pharmacy Co., Ltd. $16.1bn Excelsior Medical Co., Ltd. $8.2bn MedFirst Healthcare Services, Inc. $7.5bn
Food Science & Health Supplement	14	253.84	18.13	248.94	1.97	Grape King Bio Ltd $10.6bn TCI Co., Ltd. $8.0bn Syngen Biotech Co.,Ltd. $1.8bn
Aesthetic Medicine & Beauty Care	11	168.96	15.36	146.4	15.41	Chlitina Holding Limited $4.5bn Jourdeness Group Limited $3.0bn Shiny Brands Group Co., Ltd. $3.0bn
APIs	7	135.61	19.37	128.66	5.4	Formosa Laboratories, Inc. $4.4bn ScinoPharm Taiwan, Ltd. $3.2bn Chunghwa Chemical Synthesis & Biotech Co., Ltd. $2.1bn
Agriculture & Agricultural Science	9	124.56	13.84	129.05	-3.48	Morn Sun Feed Mill Corp. $2.9bn All Cosmos Bio-Tech Holding Corporation $2.8bn Huikwang Corporation $1.5bn
CRO Service & Genetic Testing	13	52.34	4.03	56.69	-7.67	Healthconn Corp. $1.3bn Level Biotechnology Inc. $0.7bn Genetics Generation Advancement Corp. $0.6bn
Cell Therapy	12	29.96	2.5	21.71	38.0	BIONET Corp. $1.1bn Ever Supreme Bio Technology Co., Ltd $0.8bn Taiwan Advance Bio-Pharmaceutical Inc. $0.3bn
Total	224	3187.08	14.23	3041.67	4.78